Monopar Therapeutics (MNPR) has unveiled promising preclinical data for its MNPR-101 radiopharmaceutical program, marking a significant stride in the fight against advanced cancers. The innovative program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), including a majority of triple-negative breast, colorectal, and pancreatic cancers.
The key focus of radiopharmaceutical therapy lies in maximizing the dose delivered to the tumor while minimizing impact on normal tissues. Monopar’s preclinical imaging and therapeutic efficacy data showcase substantial progress in this regard. Through meticulous optimization, the company’s in-house team has achieved heightened tumor uptake of MNPR-101-Zr, as evidenced by positron emission tomography (PET) sequential imaging.
Furthermore, preclinical studies have demonstrated compelling anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes. In both triple-negative breast cancer and pancreatic cancer models, near-complete tumor elimination was observed following a single injection of the radiopharmaceutical agent.
Encouraged by these findings, Monopar has obtained clearance to commence a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients. Andrew Cittadine, Monopar’s Chief Operating Officer, expressed optimism about the potential clinical benefits highlighted by these preclinical results, signaling a promising avenue in the pursuit of effective cancer treatments.
